Dapivirine gel

DRUG3 trials

Sponsors

International Partnership for Microbicides, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsPharmaokinetics

Phase 1

PK/PD of Single Dose Dapivirine Vaginal Film

CompletedNCT01924091

International Partnership for Microbicides, Inc.Pharmaokinetics

Start: 2013-09-30End: 2014-09-30Updated: 2017-09-08

Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

CompletedNCT03239483

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-10-26End: 2018-09-20Updated: 2021-10-19

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

CompletedNCT03393468

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2018-05-10End: 2018-12-03Updated: 2021-10-25

Related Papers

Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).

2021-10-176 citations

A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026)

AIDS Research and Human Retroviruses2021-09-097 citations